13
Views
4
CrossRef citations to date
0
Altmetric
Clinical Communication

Central serous chorioretinopathy in the fellow eye as a complication of intravitreal dexamethasone implant for the treatment of Irvine‐Gass syndrome

, MD, , MD, , MD, , MD & , MD
Pages 601-603 | Received 13 Dec 2015, Accepted 03 Apr 2016, Published online: 15 Apr 2021

References

  • Liew G, Quin G, Gillies M et al. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol 2013; 41: 201–214.
  • Yanoff M, Duker JS. Ophthalmology. 2nd edn. St. Louis, USA: Elsevier – Health Sciences Division, 2004.
  • Bellocq D, Korobelnil J, Burillon C et al. Effectiveness and safety of dexamethasone implants for post – surgical macular oedema including Irvine‐ Gass syndrome: the EPISODIC study. Br J Ophthalmol 2015; 99: 979–983.
  • Bourgault S, Chmielewska K, Tourville E. Prophylaxis and treatment of Irvine‐Gass syndrome. Clin Surg Ophthalmol 2010; 28: 48–55.
  • Heier JS, Topping TM, Baumann W et al. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000; 107: 2034–2038.
  • Negi AK, Browning AC, Vernon SA. Single perioperative triamcinolone injection versus standard postoperative steroid drops after uneventful phacoemulsification surgery: Randomized controlled trial. J Cataract Refract Surg 2006; 32: 468–474.
  • Koutsandrea CM, Moschos MM, Brouzas D et al. Intraocular triamcinolone acetonide for pseudophakic cystoid macular edema. Retina 2007; 27: 159–164.
  • Konstantopoulos A, Williams CP, Luff AJ. Outcome of intravitreal triamcinolone acetonide in postoperative cystoid macular oedema. Eye 2008; 22: 219–222.
  • Thach AB, Dugel PU, Flindall RJ. A comparison of retrobulbar versus sub‐Tenon's corticosteroid therapy for cystoid macular edema refractory to topical medications. Ophthalmology 1997; 104: 2003–2008.
  • Benitah NR, Arroyo JG. Pseudophakic cystoid macular edema. Int Ophthalmol Clin 2010; 50: 139–153.
  • Vedantham V. Periocular corticosteroid therapy: comments. Br J Ophthalmol 2004; 88: 724–725.
  • Nehme A, Lobenhofer EK, Stamer WD et al. Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics 2009; 2: 58.
  • Lu NZ, Cidlowski JA. Glucocorticoid receptor isoforms generate transcription specificity. Trends Cell Biol 2006; 16: 301–307.
  • Chung H, Hwang JJ, Koh JY et al. Triamcinolone acetonide‐mediated oxidative injury in retinal cell culture: comparison with dexamethasone. Invest Ophthalmol Vis Sci 2007; 48: 5742–5749.
  • Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: Implications for elevated intraocular pressure and cataracts. Arch Ophthalmol 2011; 129: 914–920.
  • Tsai D, Chen S, Huang C et al. Risk of central serous chorioretinopathy in adults prescribed oral corticosteroids: A population‐based study in Taiwan. Retina 2014; 34: 1867–1874.
  • Imasawa M, Ohshiro T, Gotoh T et al. Central serous chorioretinopathy following vitrectomy with intravitreal triamcinolone acetonide for diabetic macular oedema. Acta Ophthalmol Scand 2005; 83: 132–133.
  • Daruich A, Matet A, Dirani A et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Ret Eye Res 2015; 48: 82–118.
  • Kocabora MS, Durmaz S, Kandemir N. Exacerbation of central serous chorioretinopathy following intravitreal triamcinolone injection. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1783–1786.
  • Chang Y, Weng S, Chang C et al. Associations between topical ophthalmic corticosteroids and central serous chorioretinopathy: A Taiwanese population‐based study. Invest Ophth Vis Sci 2015; 56: 4083–4089.
  • Electronic Medicines Compendium. Ozurdex. [Updated 30 Mar 2015; cited 25 Nov 2015.] Available from URL: https://www.medicines.org.uk/emc/medicine/23422
  • Han JM, Hwang JM, Kim JS et al. Changes in choroidal thickness administration of high‐dose corticosteroids: A pilot study. Invest Ophthalmol Vis Sci 2014; 55: 440–445.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.